Cargando…

Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer

Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to genetic counseling, insurance coverage, and out-of-pocket costs. The GENTleMEN study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Heather H., Sokolova, Alexandra O., Gulati, Roman, Bowen, Deborah, Knerr, Sarah A., Klemfuss, Nola, Grivas, Petros, Hsieh, Andrew, Lee, John K., Schweizer, Michael T., Yezefski, Todd, Zhou, Alicia, Yu, Evan Y., Nelson, Peter S., Montgomery, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928882/
https://www.ncbi.nlm.nih.gov/pubmed/36623239
http://dx.doi.org/10.1200/PO.22.00104
_version_ 1784888732536537088
author Cheng, Heather H.
Sokolova, Alexandra O.
Gulati, Roman
Bowen, Deborah
Knerr, Sarah A.
Klemfuss, Nola
Grivas, Petros
Hsieh, Andrew
Lee, John K.
Schweizer, Michael T.
Yezefski, Todd
Zhou, Alicia
Yu, Evan Y.
Nelson, Peter S.
Montgomery, Bruce
author_facet Cheng, Heather H.
Sokolova, Alexandra O.
Gulati, Roman
Bowen, Deborah
Knerr, Sarah A.
Klemfuss, Nola
Grivas, Petros
Hsieh, Andrew
Lee, John K.
Schweizer, Michael T.
Yezefski, Todd
Zhou, Alicia
Yu, Evan Y.
Nelson, Peter S.
Montgomery, Bruce
author_sort Cheng, Heather H.
collection PubMed
description Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to genetic counseling, insurance coverage, and out-of-pocket costs. The GENTleMEN study was designed to determine the feasibility of an Internet-based, patient-driven germline genetic testing approach for men with mPC. PATIENTS AND METHODS: In this prospective cohort study, men with mPC provided informed consent via an Internet-based platform and completed a questionnaire including demographics and family cancer history. Supporting medical data were also collected. Genetic testing was performed using the Color Genomics 30-gene targeted panel of cancer predisposition genes on a mailed saliva sample. Men whose test results identified a germline pathogenic or likely pathogenic variant received results by phone or telehealth genetic counseling; other participants received results by email with an option for phone-based or telehealth genetic counseling. RESULTS: As of August 18, 2021, 816 eligible men were consented, of whom 68% (551) completed genetic testing, and 8.7% (48 of 551) were found to carry a pathogenic or likely pathogenic variant in a germline DNA repair gene: CHEK2 (17), BRCA2 (15), ATM (6), NBN1 (3), BRCA1 (2), PALB2 (2), PMS2 (2), and MSH6 (1). Participants were more likely to complete the testing process if they were non-Hispanic White, married, highly educated, or from a higher-income bracket. CONCLUSION: Here, we show the feasibility of delivering germline (inherited) genetic testing by a voluntary, patient-driven, Internet-based platform to men with mPC. Preliminary results show rates of germline DNA repair mutations, consistent with other cohorts. Although feasible for some, reduced steps for participation, more dedicated diverse outreach and participant support, and identification and addressing of additional barriers is needed to ensure equitable access and optimization.
format Online
Article
Text
id pubmed-9928882
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-99288822023-02-16 Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer Cheng, Heather H. Sokolova, Alexandra O. Gulati, Roman Bowen, Deborah Knerr, Sarah A. Klemfuss, Nola Grivas, Petros Hsieh, Andrew Lee, John K. Schweizer, Michael T. Yezefski, Todd Zhou, Alicia Yu, Evan Y. Nelson, Peter S. Montgomery, Bruce JCO Precis Oncol ORIGINAL REPORTS Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to genetic counseling, insurance coverage, and out-of-pocket costs. The GENTleMEN study was designed to determine the feasibility of an Internet-based, patient-driven germline genetic testing approach for men with mPC. PATIENTS AND METHODS: In this prospective cohort study, men with mPC provided informed consent via an Internet-based platform and completed a questionnaire including demographics and family cancer history. Supporting medical data were also collected. Genetic testing was performed using the Color Genomics 30-gene targeted panel of cancer predisposition genes on a mailed saliva sample. Men whose test results identified a germline pathogenic or likely pathogenic variant received results by phone or telehealth genetic counseling; other participants received results by email with an option for phone-based or telehealth genetic counseling. RESULTS: As of August 18, 2021, 816 eligible men were consented, of whom 68% (551) completed genetic testing, and 8.7% (48 of 551) were found to carry a pathogenic or likely pathogenic variant in a germline DNA repair gene: CHEK2 (17), BRCA2 (15), ATM (6), NBN1 (3), BRCA1 (2), PALB2 (2), PMS2 (2), and MSH6 (1). Participants were more likely to complete the testing process if they were non-Hispanic White, married, highly educated, or from a higher-income bracket. CONCLUSION: Here, we show the feasibility of delivering germline (inherited) genetic testing by a voluntary, patient-driven, Internet-based platform to men with mPC. Preliminary results show rates of germline DNA repair mutations, consistent with other cohorts. Although feasible for some, reduced steps for participation, more dedicated diverse outreach and participant support, and identification and addressing of additional barriers is needed to ensure equitable access and optimization. Wolters Kluwer Health 2023-01-09 /pmc/articles/PMC9928882/ /pubmed/36623239 http://dx.doi.org/10.1200/PO.22.00104 Text en © 2023 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle ORIGINAL REPORTS
Cheng, Heather H.
Sokolova, Alexandra O.
Gulati, Roman
Bowen, Deborah
Knerr, Sarah A.
Klemfuss, Nola
Grivas, Petros
Hsieh, Andrew
Lee, John K.
Schweizer, Michael T.
Yezefski, Todd
Zhou, Alicia
Yu, Evan Y.
Nelson, Peter S.
Montgomery, Bruce
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
title Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
title_full Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
title_fullStr Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
title_full_unstemmed Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
title_short Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
title_sort internet-based germline genetic testing for men with metastatic prostate cancer
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928882/
https://www.ncbi.nlm.nih.gov/pubmed/36623239
http://dx.doi.org/10.1200/PO.22.00104
work_keys_str_mv AT chengheatherh internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT sokolovaalexandrao internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT gulatiroman internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT bowendeborah internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT knerrsaraha internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT klemfussnola internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT grivaspetros internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT hsiehandrew internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT leejohnk internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT schweizermichaelt internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT yezefskitodd internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT zhoualicia internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT yuevany internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT nelsonpeters internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer
AT montgomerybruce internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer